Dr. Neil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
120 Green Ln
Haverford, PA 19041Phone+1 484-412-8130
Summary
- I am a board certified internist and gastroenterologist, as well as a bench scientist and biotech/pharmaceutical executive, board member and investor. I have spent most of my career in basic and applied research, drug discovery and drug development. I am currently CEO/Chairman of a clinical stage public biotechnology company in the Philadelphia region (Avalo Therapeutics NASDAQ:AVTX) and member of the board of directors of Celldex, NASDAQ:CLDX).
Clinical Expertise
- Internal medicine, Gastroenterology, Hepatology, Immunology, Oncology
Education & Training
Research Institute of Scripps ClinicFellowship, 1985 - 1987- University of TorontoFRCP(C), Gastroenterology, 1982 - 1984
- University of TorontoInternship, 1980 - 1982
University Saskatchewan Royal HospitalClass of 1979
Certifications & Licensure
PA State Medical License 1994 - 2024
IA State Medical License 1988 - 1995- American Board of Internal Medicine Gastroenterology
Clinical Trials
- An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II Start of enrollment: 2023 Apr 10
- A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II Start of enrollment: 2022 Jul 28
- A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma. Start of enrollment: 2022 Feb 24
Publications & Presentations
PubMed
- 23 citationsRealigning the LIGHT signaling network to control dysregulated inflammation.Carl F Ware, Michael Croft, Garry A Neil
The Journal of Experimental Medicine. 2022-07-04 - 28 citationsLevels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS.David S. Perlin, Inbal Zafir-Lavie, Lori Roadcap, Shane Raines, Carl F. Ware
Msphere. 2020-08-26 - 10 citationsRandomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.David S Perlin, Garry A Neil, Colleen Anderson, Inbal Zafir-Lavie, Shane Raines
The Journal of Clinical Investigation. 2022-02-01
Journal Articles
- Successful Intracranial Delivery of Trastuzumab by Gene-Therapy for Treatment of HER2-Positive Breast Cancer Brain MetastasesGarry Neil, MD, ScienceDirect
Press Mentions
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaOctober 8th, 2024- Avalo Reports 2022 Financial Results and Provides Business UpdatesMarch 29th, 2023
- Avalo Announces It Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic AsthmaJanuary 17th, 2023
- Join now to see all
Research History
- Associate Director, Ludwig Institute for Cancer ResearchAssociate Director of Ludwig Institute for Cancer Ressearch, Toronto Branch1987 - 1989
Professional Memberships
- Fellow
- Fellow
Industry Relationships
- Member Board of Directors, CelldexBoard Member Celldex2022 - Present
- CEO and Chairman, Avalo TherapeuticsCEO of a small public biotech company developing biologic therapies for immunologic diseases2013 - Present
- Board Member and Chair, Arena Pharmaceuticals2016 - 2022
External Links
- LinkedInhttps://www.linkedin.com/in/garry-neil-1070101
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
